Needham & Company LLC Reaffirms Hold Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Needham & Company LLC reissued their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a report issued on Thursday,Benzinga reports.

Separately, Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $24.16 on Thursday. Amphastar Pharmaceuticals has a 52-week low of $22.74 and a 52-week high of $53.96. The company has a 50 day moving average of $28.68 and a two-hundred day moving average of $38.14. The company has a market cap of $1.15 billion, a P/E ratio of 8.05, a P/E/G ratio of 2.19 and a beta of 0.79. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth $38,000. Tower Research Capital LLC TRC lifted its position in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after buying an additional 348 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in shares of Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock valued at $50,000 after buying an additional 361 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.